Acyclovir and hydrocortisone Topical application and Capastat

• Generic Name: acyclovir / hydrocortisone topical
• Dosage Forms: n.a.
• Other Brand Names: Xerese

Acyclovir and hydrocortisone topical combination is used to treat the symptoms of herpes simplex virus infection on the lips and around the mouth (cold sores). Although acyclovir and hydrocortisone will not cure herpes simplex, it may help the sores to heal faster and relieve some of the pain and discomfort. Acyclovir is an antiviral agent (treats a virus) and hydrocortisone is a steroid (cortisone-like) medicine.

Acyclovir and hydrocortisone is available only with your doctor's prescription.

• Generic Name: capreomycin
• Dosage Forms: injection, powder, for solution
• Other Brand Names: Capastat Sulfate

Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents.

Second-line agent used in treatment of drug-resistant TB caused by Mycobacterium tuberculosis known or presumed to be susceptible to capreomycin.

For initial treatment of active TB caused by drug-susceptible M. tuberculosis, recommended multiple-drug regimens consist of an initial intensive phase (2 months) and a continuation phase (4 or 7 months). Although the usual duration of treatment for drug-susceptible pulmonary and extrapulmonary TB (except disseminated infections and TB meningitis) is 6–9 months, ATS, CDC, and IDSA state that completion of treatment is determined more accurately by the total number of doses and should not be based solely on the duration of therapy. A longer duration of treatment (e.g., 12–24 months) usually is necessary for infections caused by drug-resistant M. tuberculosis.

Patients with treatment failure or drug-resistant M. tuberculosis, including multidrug-resistant (MDR) TB (resistant to both isoniazid and rifampin) or extensively drug-resistant (XDR) TB (resistant to both isoniazid and rifampin and also resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial such as capreomycin, kanamycin, or amikacin), should be referred to or managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.